RecruitingPhase 2NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
Sponsor
M.D. Anderson Cancer Center
Enrollment
295 participants
Start Date
Feb 13, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Pentoxifylline, a drug called Pravastatin, and others for people with fibrosis and lymphedema. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPravastatin
Given by PO
DRUGPentoxifylline
Given by PO
DRUGTocopherol
Given by PO
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06494111
Related Trials
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
NCT067250306 locations
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
NCT07816185
Effectiveness of a Tele-Rehabilitation-Based Exercise and Self-Lymphatic Drainage Program Supported by Self-Management for Breast Cancer-Related Lymphedema
NCT07794904
Gut Microbiota in Patients With Limb Lymphedema and Recurrent Lymphangitis
NCT062289371 location
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT073331831 location